Group 1 - The company has successfully won bids for eight major products in the national traditional Chinese medicine procurement alliance, covering treatment areas such as cardiovascular diseases, respiratory diseases, and digestive system diseases, which are commonly used in clinical applications and included in medical insurance and essential drug lists [2] - The successful bidding aligns the products with DRG/DIP payment requirements, providing better medication options for more patients and enhancing future market demand, market coverage, and sales potential for the company's products [2] - The traditional Chinese medicine granule industry is entering a period of deep adjustment characterized by declining sales, with the company's sales revenue for traditional Chinese medicine granules decreasing by 14.4% due to multiple policy impacts [2] Group 2 - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [3] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26, and the company declared an interim dividend of RMB 0.43 per share for 2026 [3]